The proteasome inhibitor bortezomib represents an important advance for the treatment of both previously untreated and treated patients with multiple myeloma (MM). However, nearly all patients eventually relapse or become refractory to bortezomib therapy, so there is a continued need for new therapies. Vorinostat is a potent oral inhibitor of Class I and II histone deacetylases (HDACs) and has demonstrated antiproliferative and proapoptotic activity alone and in combination with bortezomib in preclinical models of MM. Preliminary results from an open-label, multicenter Phase I trial of oral vorinostat in combination with bortezomib have shown that the combination is generally well tolerated and effective in heavily pretreated patients with advanced MM (
Disclosures: Weber:Celgene: Honoraria, Research Funding, Speakers Bureau; Millenium: Honoraria, Research Funding, Speakers Bureau; Merck: Research Funding, Speakers Bureau. Schiller:Vion: Research Funding; Millenium: Research Funding; Celgene: Research Funding; UGI Pharma: Research Funding; Merck: Research Funding; Denzyme: Research Funding. Chiacchierini:Merck: Employment. Reiser:Merck: Employment. Oerth:Merck: Employment. Garcia-Vargas:Merck: Employment. Rizvi:Merck: Employment. Off Label Use: Vorinostat is a histone deacetylase (HDAC) inhibitor that was approved in the FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies.